NCT00635973View on ClinicalTrials.gov

Open-Label Extension of Other SZ1839 (Iressa) Trials

PHASE3CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

February 29, 2000

Study Completion Date

October 31, 2003

Conditions

Cancer

Interventions

DRUG

Gefitinib (Iressa)

Iressa

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY